Savr V. Bugurov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Savr V. Bugurov has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alexander A. Gostev
Meshalkin National Medical Research Center
1 shared publication - Alexey V. Cheban
Meshalkin National Medical Research Center Novosibirsk Russian Federation
1 shared publication - Andrey Anatol'Evich Karpenko
Федеральное государственное бюджетное учреждение «Федеральный научно- клинический центр физико-химической медицины имени академика Ю.М. Лопухина» Федерального медико-биологического агентства, Москва, Российская Федерация
1 shared publication - Artem A. Rabtsun
Meshalkin National Medical Research Center
1 shared publication - Olesya S. Osipova
Department of Vascular Pathology and Hybrid Technologies, Meshalkin National Medical Research Center of the Ministry of Healthcare of the Russian Federation, Novosibirsk, Russia
1 shared publication - Pavel V. Ignatenko
Meshalkin National Medical Research Center
1 shared publication
Latest Publications
- 17 May 2022
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 45 (7) , 929-938
Bypass Versus Interwoven Nitinol Stents for Long Femoro-Popliteal Occlusions: A Propensity Matched Analysis
Purpose To compare femoro-popliteal bypass and interwoven nitinol stenting for long occlusions of the femoro-popliteal segment. Materials and Methods Single center retrospective propensity matching analysis of the symptomatic patients with long occlusion of the femoro-popliteal segment (> 20 cm), who underwent stenting with interwoven nitinol stent or femoro-popliteal bypass from 2012 to 2020. Primary endpoints: primary patency, primary-assisted patency, secondary patency. Secondary endpoints: major adverse cardiovascular events, major adverse limb events, primary sustained clinical improvement, survival. Results A total of 437 patients were enrolled: 294 in the bypass group and 143 in the endovascular therapy (EVT) group. After propensity score matching, 264 and 113 patients remained in the groups, respectively. A median occlusion length was 250 mm. One-year and two-year primary and secondary patency rates were comparable in both groups (two-year primary patency: 68.5% for bypass vs. 68.9% for EVT, p = 1.00). In the “above the knee” subgroup analysis, two-year secondary patency was higher in the EVT group than in the bypass group (90.9% vs. 77.5%, p = 0.048). In “below-the-knee” subgroup analysis, primary and primary assisted patency were statistically significantly higher in the EVT group than in artificial bypass subgroup (66.7% vs. 42.4%, p = .046 and 76.7% vs. 45.5%, p = .011, respectively). However, compared to autovenous bypass, the EVT group showed lower primary patency rates, although the differences are not significant. Conclusion A nonselective endovascular strategy can allow for regular successful treatment of femoro-popliteal lesions longer than 25 cm.
- 17 May 2022
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 45 (7) , 929-938
Bypass Versus Interwoven Nitinol Stents for Long Femoro-Popliteal Occlusions: A Propensity Matched Analysis
Purpose To compare femoro-popliteal bypass and interwoven nitinol stenting for long occlusions of the femoro-popliteal segment. Materials and Methods Single center retrospective propensity matching analysis of the symptomatic patients with long occlusion of the femoro-popliteal segment (> 20 cm), who underwent stenting with interwoven nitinol stent or femoro-popliteal bypass from 2012 to 2020. Primary endpoints: primary patency, primary-assisted patency, secondary patency. Secondary endpoints: major adverse cardiovascular events, major adverse limb events, primary sustained clinical improvement, survival. Results A total of 437 patients were enrolled: 294 in the bypass group and 143 in the endovascular therapy (EVT) group. After propensity score matching, 264 and 113 patients remained in the groups, respectively. A median occlusion length was 250 mm. One-year and two-year primary and secondary patency rates were comparable in both groups (two-year primary patency: 68.5% for bypass vs. 68.9% for EVT, p = 1.00). In the “above the knee” subgroup analysis, two-year secondary patency was higher in the EVT group than in the bypass group (90.9% vs. 77.5%, p = 0.048). In “below-the-knee” subgroup analysis, primary and primary assisted patency were statistically significantly higher in the EVT group than in artificial bypass subgroup (66.7% vs. 42.4%, p = .046 and 76.7% vs. 45.5%, p = .011, respectively). However, compared to autovenous bypass, the EVT group showed lower primary patency rates, although the differences are not significant. Conclusion A nonselective endovascular strategy can allow for regular successful treatment of femoro-popliteal lesions longer than 25 cm.